Prospective observational study of stool metagenome and metabolome analysis of patients with inflammatory bowel disease aiming to develop IBD omics score for the predict of relapse

Prospective observational study of stool metagenome and metabolome analysis of patients with inflammatory bowel disease aiming to develop IBD omics score for the predict of relapse - Prospective observational study of stool metagenome and metabolome analysis of patients with inflammatory bowel disease aiming to develop IBD omics score for the predict of relapse

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000044047

Enrollment

100

Registered

2021-05-07

Start date

2020-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

inflammatory bowel disease

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients in clinical remission(Crohn's disease: maintain Harvey-Bradshaw index 3 or less for 3 months or more. Ulcerative colitis: Maintain Partial Mayo 1 and less for 3 months or more. Patients 16 years and over at the time of consent acquisition Patients who voluntarily consented in writing after receiving sufficient explanation for participation in this study

Exclusion criteria

Exclusion criteria: Patients with unconfirmed diagnosis Patients receiving steroids Patients taking antithrombotic drugs Patients who do not consent to this study Patients judged to be ineligible by the research director

Design outcomes

Primary

Measure	Time frame
Analysis of omics data of IBD patients in remission: Use metagenomic analysis, metabolome analysis, and transcriptome analysis at enrollment	—

Secondary

Measure	Time frame
The development of IBD omics score for predict of relapse: Examine IBD patients who maintained remission by 52 weeks and IBD patients who relapsed within 52 weeks using metagenomic analysis, metabolome analysis, and transcriptome analysis.	—

Countries

Japan

Contacts

Public ContactKohei Wagasuma

Sapporo Medical University School of Medicine Department of Gastroenterology and Hepatology

k.wagatsuma@sapmed.ac.jp011-611-2111

Outcome results